ArticleJournal of menopausal medicine2018
Establishment of Effective Mouse Model of Premature Ovarian Failure Considering Treatment Duration of Anticancer Drugs and Natural Recovery Time.
Article in Journal of menopausal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 57 citations in OpenAlex.
- Sex-dependent and long-term effects of cisplatin on bone mineral density in juvenile mice.Pharmacological reports : PR · 2026Article
- Oral Supplementation with a Kudzu Root-Black Soybean Blend Attenuates Ovarian Dysfunction in Mice: Implications for Its Potential Use as a Dietary Supplement in Animal Nutrition.Animals : an open access journal from MDPI · 2026Article
- Article
- Dominant follicle-targeted nanocarriers for GH delivery to alleviate premature ovarian insufficiency.Materials today. Bio · 2025Article
- Growth Hormone Improves Ovarian Follicle Health in Premature Ovarian Failure Mice by Reducing Apoptosis : (GH Improves Ovarian Follicle Health in POF Mice by Reducing Apoptosis).Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Human Placental Stem Cells Derived Exosomes Xenograft Recover Ovarian Function in Training-induced Premature Ovarian Insufficiency Rats.Current stem cell research & therapy · 2025Article
- An overview of different methods to establish a murine premature ovarian failure model.Animal models and experimental medicine · 2024Review
- Loss of Calponin 2 causes premature ovarian insufficiency in mice.Journal of ovarian research · 2024Article
- Research progress of extracellular vesicles in the treatment of ovarian diseases (Review).Experimental and therapeutic medicine · 2024Review
- Comparison the therapeutic effects of bone marrow CD144BioImpacts : BI · 2023Article
- Prdm9 deficiency of rat oocytes causes synapsis among non-homologous chromosomes and aneuploidy.Mammalian genome : official journal of the International Mammalian Genome Society · 2022Article
- Mechanisms of action of Zishen Yutai pills in treating premature ovarian failure determined by integrating UHPLC-Q-TOF-MS and network pharmacology analysis.BMC complementary medicine and therapies · 2022Article
- Ubiquitin-like modifier 1 ligating enzyme 1 relieves cisplatin-induced premature ovarian failure by reducing endoplasmic reticulum stress in granulosa cells.Reproductive biology and endocrinology : RB&E · 2022Article
- Induction of a rat model of premature ovarian insufficiency using D-galactose feeding during the critical periods of development: A pilot study.International journal of reproductive biomedicine · 2022Article
- Electro-Acupuncture Regulates Metabolic Disorders of the Liver and Kidney in Premature Ovarian Failure Mice.Frontiers in endocrinology · 2022Article
- Human adipose-derived stromal cells transplantation prolongs reproductive lifespan on mouse models of mild and severe premature ovarian insufficiency.Stem cell research & therapy · 2021Article
- Autologous transplantation of thecal stem cells restores ovarian function in nonhuman primates.Cell discovery · 2021Article
- Effects of low intensity pulsed ultrasound on expression of B-cell lymphoma-2 and BCL2-Associated X in premature ovarian failure mice induced by 4-vinylcyclohexene diepoxide.Reproductive biology and endocrinology : RB&E · 2021Article
- Premature ovarian insufficiency: pathogenesis and therapeutic potential of mesenchymal stem cell.Journal of molecular medicine (Berlin, Germany) · 2021Review
- Human umbilical cord mesenchymal stem cells restore the ovarian metabolome and rescue premature ovarian insufficiency in mice.Stem cell research & therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study was aimed to establish the most effective premature ovarian failure (POF) mouse model using Cyclophosphamide (CTX), busulfan (Bu), and cisplatin considering treatment duration of anticancer drugs and natural recovery time.
methodsPOF was induced by intraperitoneally injecting CTX (120 mg/kg)/Bu (12 mg/kg) for 1 to 4 weeks or cisplatin (2 mg/kg) for 3 to 14 days to C57BL/6 female mice aged 6 to 8 weeks. Controls were injected with equal volume of saline for the same periods. Body weight was measured every week, and ovarian and uterine weights were measured after the last injection of anticancer drug. To assess ovarian function, POF-induced mice were superovulated with pregnant mare serum gonadotropin and human chorionic gonadotropin, and then mated with male. After 18 hours, zygotes were retrieved and cultured for 4 days. Finally, the mice were left untreated for a period of times after the final injection of anticancer drug, and the time for natural recovery of ovarian function was evaluated.
resultsAfter 2 weeks of CTX/Bu injection, ovarian and uterine weights, and ovarian function were decreased sharply. Cisplatin treatment for 10 days resulted in a significant decrease in ovarian and uterine weight, and ovarian function. When POF was induced for at least 2 weeks for CTX/Bu and for at least 10 days for cisplatin, ovarian function did not recover naturally for 2 weeks and 1 week, respectively.
conclusionsThese results suggest that CTX/Bu should be treated for at least 2 weeks and cisplatin for at least 10 days to establish the most effective primary ovarian insufficiency mouse model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.